BioWorld

March 5, 2010

GTx Mum as Merck Discontinues Phase II SARM Ostarine/MK-2866

Four months after GTx Inc. suffered a devastating FDA setback with lead program toremifene, the biotech's second program - Phase II muscle loss drug Ostarine/MK-2866 - has been discontinued by partner Merck and Co. Inc. (BioWorld Today) Read More

Senators Agree on Language in Long-Debated Patent Reform

News Times Three: SpePharm Adds Product, Partner, Money

Vaxart Raises $12.5M in Series B to Take Oral Vaccine into Clinic

Columbia Labs Getting $92.5M in Watson Progesterone Deal

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 12, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...